Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - Nihon Pharmaceutical

Drug Profile

Immune globulin - Nihon Pharmaceutical

Alternative Names: Dried polyethylene glycol-treated human immunoglobulin - Nihon Pharmaceutical; Immunoglobulin intravenous - Nihon Pharmaceutical; Kenketu Glovenin-I; Kenketu Glovenin-I-Nichiyaku; NPB-01

Latest Information Update: 16 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nihon Pharmaceutical
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Agammaglobulinaemia; Bullous pemphigoid; Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Motor neuron disease; Pemphigus; Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • Phase II Neuromyelitis optica

Most Recent Events

  • 01 Sep 2015 Nihon Pharmaceutical completes a phase III trial for Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (NCT01824251)
  • 01 Jun 2015 Nihon Pharmaceutical completes a phase III trial for Motor neuron disease in Japan (NCT01827072)
  • 01 Jun 2014 Nihon Pharmaceutical completes a phase III trial in Stevens-Johnson syndrome and Toxic epidermal necrolysis in Japan (NCT01696500)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top